alexa
Reach Us +1(850)754-6199
Discovery Of Novel Leads As Dual Acting Inhibitors Of Acetylcholinesterase Using Pharmacophore Modeling, Docking Consensus And 3D-QSAR Studies For Alzheimer?s Disease | 4737
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Discovery of novel leads as dual acting inhibitors of acetylcholinesterase using pharmacophore modeling, docking consensus and 3D-QSAR studies for Alzheimer?s disease

3rd World Congress on Biotechnology

Elvis A. F. Martis, Rakesh C. Chandarana, Premlata K. Ambre, Raghuvir R. S. Pissurlenkar and Evans C. Coutinho

Posters: Agrotechnol

DOI: 10.4172/2155-952X.S1.020

Abstract
Alzheimer?s disease (AD) is the most debilitating and chronic irreversible neurological condition, characterized by dementia and cognitive impairment due to the depletion of acetylcholine in the nervous system. The existing experimental data obtained from animal studies and other neurological studies are all indicative that, the main cause of dementia is the decrease of the integrity of the cholinergic inputs, which is believed to be due to its rapid hydrolysis of acetylcholine in the synaptic clefts by acetylcholinesterase (AChE).The limited number of drugs available for the treatment of AD, and many recent studies which have provided ample evidences of the molecular mechanisms of the progression of the disease has been our driving force for designing novel agents for treatment of AD. The structural insights provided by many studies of our target enzyme, AChE, in recent times have boosted our confidence of designing more potent and safer agents to tackle the disease more efficiently. The objective was to identify hit candidates with probable AChE inhibitors by a process of virtual screening the public databases based on pharmacophore hypothesis (positive ionizable group, two hydrogen bond acceptors, and two aromatic rings). The relevant hypothesis was built using the known inhibitors of AChE as templates to investigate the pharmacophoric elements that represent the critical receptor-ligand interactions. The identified hits were predicted for activity by the 3D-QSAR models i.e. CoRIA {Comparative Residue Interaction Analysis} and later short listed for in vitro testing. The most potent predicted compounds were procured from Enamine and tested by the Ellman?s colorimetric method. The inhibitory concentration for the most active candidates was 1.7, 21.14, and 35.4 μM.
Biography
Elvis A. F. Martis is currently pursuing his Master of Pharmaceutical Sciences with specialization in Pharmaceutical Chemistry from University of Mumbai. He is currently working on various in silico methods to develop potent therapeutic agents for Alzheimer?s disease. He has authored 11 papers which include four Research articles, six Review articles and one book chapter.
Top